Of 8 guidance figures from Johnson & Johnson's earnings releases that Stock Atlas has scored against the reported result, 7 came in above the guide, 1 in range and 0 below. It met or beat its own guidance 100% of the time.
| Period | Measure | Guided | Reported | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $93.50B to $93.90B | $94.19B | above |
| FY2024 | Revenue | $88.00B to $88.40B | $88.82B | above |
| FY2023 | Estimated Reported Sales | $83.60B to $84.00B | $85.16B | above |
| FY2022 | Estimated Reported Sales | $93.30B to $94.30B | $94.94B | above |
| FY2021 | Estimated Reported Sales | $90.60B to $91.60B | $93.78B | above |
| FY2020 | Estimated Reported Sales | $77.50B to $80.50B | $82.58B | above |
| FY2018 | Revenue | $81.00B to $81.40B | $81.58B | above |
| FY2017 | Revenue | $76.20B to $76.50B | $76.45B | in range |
Above means the reported figure beat the top of the range, in range that it landed inside it or on a point guide, below that it missed. Every guide and revision, and screens across companies, are in the research platform.
Do companies beat their own guidance? The study · Back to Johnson & Johnson financials
The week's biggest guidance misses, KPI surprises and one chart.
Stock Atlas, “Johnson & Johnson (JNJ) guidance record”, stockatlas.com/companies/JNJ/guidance/, data as of 3 November 2026. Links to this page are welcome.
